Since in patient-derived in vivo models of glioblastoma, CREB1 levels have been found to determine the expression of TGFB2, CREB1 has been proposed a biomarker to stratify GBM patients for anti-TGF-β treatments and eventually as a therapeutic target in anti-TGF-β therapies [48]. The gene discussed is TGFB2; the disease is glioblastoma.